The relationship between opioid and sugar intake: Review of evidence and clinical applications

Journal of Opioid Management

Volumn 6, Issue 6, 2010, Pages 445-452

  Mysels, David J ^a,b   Sullivan, Maria A ^b  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b New York State Psychiatric Institute ^*  (United States)

Author keywords

Analgesia; Diabetes; Opioid; Sugar; Weight gain

Indexed keywords

17 METHYLNALTREXONE; BETA ENDORPHIN; BUPRENORPHINE; DIAMORPHINE; GLUCOSE; LEPTIN; MELANOCORTIN; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALMEFENE; NALOXONE; OPIATE;

ANALGESIA; ANIMAL BEHAVIOR; BODY MASS; DECREASED APPETITE; DRUG EFFECT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEROIN DEPENDENCE; HUMAN; NONHUMAN; OBESITY; REVIEW; SIDE EFFECT; SUGAR INTAKE; SWEETNESS; TOOTH DISEASE; WEIGHT GAIN;

ANALGESIA; ANALGESICS, OPIOID; BETA-ENDORPHIN; BLOOD GLUCOSE; CARBOHYDRATES; HUMANS; OPIOID-RELATED DISORDERS; RECEPTORS, OPIOID, MU; WEIGHT GAIN;

EID: 79551519607     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2010.0043     Document Type: Review

References (79)

1. Borg L, Kravets I, Kreek MJ: The pharmacology of long-acting as contrasted with short-acting opioids. In Ries RK, Fiellin DA, Miller SC, et al. (eds.): Principles of Addiction Medicine. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2009: 117-131.
2. Kolarzyk E, Chrostek MJ, Pach D, et al.: Assessment of daily nutrition ratios of opiate-dependent persons before and after 4 years of methadone maintenance treatment. Przegl Lek. 2005; 62(6): 368-372.
3. Zador D, Lyons Wall PM, Webster I: High sugar intake in a group of women on methadone maintenance in South Western Sydney, Australia. Addiction. 1996; 9(7): 1053-1061.
4. Nolan LJ, Scagnelli LM: Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Subst Use Misuse. 2007; 42: 1555-1566.
5. Morabia A, Fabre J, Chee E, et al.: Diet and opiate addiction: A quantitative assessment of the diet of non-institutionalized opiate addicts. Br J Addict. 1989; 84:173-180.
6. Bogucka-Bonikowska A, Baran-Furga H, Chmielewska K, et al.: Taste function in methadone-maintained opioid-dependent men. Drug Alcohol Depend. 2002; 68: 113-117.
7. Dum J, Gramsch CH, Herz A: Activation of hypothalamic B-endorphin pools by reward induced by highly palatable food. Pharmacol Biochem Behav. 1983; 18: 443-447.
8. Bodnar RJ, Glass MJ, Ragnauth A, et al.: General, mu and kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions. Brain Res. 1995; 700: 205-212.
9. Koch JE, Glass MJ, Cooper ML, et al.: Alterations in deprivation, glucoprivic and sucrose intake following general, mu and kappa opioid antagonists in the hypothalamic paraventricular nucleus of rats. Neuroscience. 1995; 66(4): 951-957.
10. Kelley AE, Bless EP, Swanson CJ: Investigation into the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. J Pharmacol Exp Ther. 1996; 278(3): 1499-1507.
11. H. Echo JA, Lamonte N, Ackerman TF, et al.: Alterations in food intake elicited by GABA and opioid agonists and antagonists administered into the entrai tegmental area region of rats. Physiol Behav. 2002; 76: 107-116. (Pubitemid 34521816)
12. Zhang M, Kelley AE: Intake of saccharin, salt, and ethanol solutions is increased by infusion of a mu opioid agonist into the nucleus accumbens. Psychopharmacology. 2002; 159: 415-423. (Pubitemid 34143366)
13. Colantuoni C, Schwenker J, McCarthy J, et al.: Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain. Neuroreport. 2001; 12: 3549-3552. (Pubitemid 33065496)
14. Spangler R, Wittkowski KM, Goddard NL, et al.: Opiate-like effects of sugar on gene expression in reward areas of the rat brain. Mol Brain Res. 2004; 124: 134-142.
15. Avena NM, Rada P, Hoebel BG: Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake. Neurosci Behav Rev. 2008; 32: 20-39. (Pubitemid 350160955)
16. Yeomans MR, Wright P, Macleod HA, et al.: Effects of nalmefene on feeding in humans. Psychopharmacology. 1990; 100: 426-432.
17. Gosnell BA, Krahn DD: The effects of continuous naltrexone infusions on diet preferences are modulated by adaptation to the diets. Physiol Behav. 1992; 51(2): 239-244.
18. Drewnowski A, Krahn D, Demitrack MA, et al.: Naloxone, an opiate blocker, reduces consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr. 1995; 61: 1206-1212.
19. Yeomans MR, Gray RW: Opioid peptides and the control of human ingestive behavior. Neurosci Behav Rev. 2002; 26: 713-728.
20. Sahr AE, Sindelar DK, Alexander-Chacko JT, et al.: Activation of mesolimbic dopamine neurons during novel and daily limited access to palatable food is blocked by the opioid antagonist LY255582. Am J Physiol Regul Integr Comp Physiol. 2008; 295: R463-R471.
21. Gaiardi M, Gubellini C, Bartoletti M: Taste conditioning effects of buprenorphine in morphine-naïve and morphine-experienced rats. Pharmacol Res. 1998; 37(4): 303-307. (Pubitemid 28230426)
22. Comer SD, Evans SM, Pudiak CM, et al.: Effects of buprenorphine on candy and sweetened fluid self-administration by rhesus monkeys. Psychopharmacology. 2002; 164: 200-206.
23. Mello NK, Lukas SE, Kamien JB, et al.: The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 1992; 260:1185-1193.
24. Hood S, Sorge RE, Stewart J: Chronic buprenorphine reduces the response to sucrose-associated cues in nonfood-deprived rats. Pharmacol Biochem Behav. 2007; 86: 566-575. (Pubitemid 46466890)
25. Sapira JD: The narcotic addict as a medical patient. Am J Med. 1968; 45: 555-588.
26. Lieblich I, Yirmiya R, Liebeskind JC: Intake of and preference for sweet solutions are attenuated in morphine-withdrawn rats. Behav Neurosci. 1991; 105(6): 965-970.
27. Rajs J, Petersson A, Thiblin I, et al.: Nutritional status of deceased illicit drug addicts in Stockholn, Sweden - A longitudinal medicolegal study. J Forensic Sci. 2004; 49(2): 1-10. (Pubitemid 38298459)
28. Mohs, ME, Watson RR, Leonard-Green T: Nutritional effects of marijuana, heroin, cocaine, and nicotine. J Am Diet Assoc. 1990; 90: 1261-1267.
29. Levine AS, Atkinson RL: Opioids in the regulation of food intake and energy expenditure. Fed Proc. 1987; 46(1): 159-161.
30. Atkinson RL: Opioid regulation of food intake and body weight in humans. FedProc. 1987; 46(1): 178-182. (Pubitemid 17056340)
31. Yuan CS, Wang CZ, Attele A, et al.: Methylnaltrexone reduced body weight gain in ob/ob mice. J Opioid Manage. 2009; 5(4): 213-218.
32. David CA, Levitan RD, Reid C, et al.: Dopamine for 'wanting' and opioids for 'liking': A comparison of obese adults with and without binge eating. Obesity. 2009; 17(6): 1220-1225.
33. Shalev U, Yap J, Shaham Y: Leptin attenuates acute food deprivation-induced relapse to heroin seeking. J Neurosci. 2001; 21(4): RC129.
34. Trinko R, Sears RM, Guarnieri DJ, et al.: Neural mechanisms underlying obesity and drug addiction. Physiol Behav. 2007; 91: 499-505. (Pubitemid 47247782)
35. Belknap JK, Crabbe JC, Young ER: Voluntary consumption of ethanol in 15 inbred mouse strains. Psychopharmacology. 1993; 112: 503-510. (Pubitemid 23324174)
36. Acosta MC, Manubay J, Levin FR: Pediatric obesity: Parallels with addiction and treatment recommendations. Harv Rev Psychiatry. 2008; 16(2): 80-96.
37. Reed JL, Ghodse AH: Oral glucose tolerance and hormonal response in heroin-dependent males. Br Med J. 1973; 2: 582-585.
38. Willenbring ML, Morely JE, Krahn DD, et al.: Psychoneuroendocrine effects of methadone maintenance. Psychoneuroendocrinology. 1989; 14(5): 371-379.
39. Ceriello A, Giugliano D, Passariello N, et al.: Impaired glucose metabolism in heroin and methadone users. Horm Metab Res. 1987; 19(9): 430-433.
40. Sullivan SN, Lee MG, Bloom SR, et al.: Reduction by morphine of human postprandial insulin release is secondary to inhibition of gastrointestinal motility. Diabetes. 1986; 35(3): 324-328.
41. Mehendale SR, Yuan CS: Opioid-induced gastrointestinal dysfunction. Dig Dis. 2006; 24: 105-112.
42. Sadava D, Alonso D, Hong H, et al.: Effects of methadone addiction on glucose metabolism in rats. Gen Pharmacol. 1997; 28(1): 27-29. (Pubitemid 27016055)
43. Giugliano D: Morphine, opioid peptides, and pancreatic islet function. Diabetes Care. 1984; 7(1): 92-98.
44. Bullingham RES, McQuay HJ, Dwyer D, et al.: Sublingual buprenorphine used postoperatively: Clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol. 1981; 12: 117-122.
45. Fareed A, Casarela J, Amar R, et al.: Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract. 2009; 15: 227-234.
46. Tiras S, Haas V, Chevret L, et al.: Nonketotic hyperglycemic coma in toddlers after unintentional methadone ingestion. Ann Emerg Med. 2006; 48(4): 448-451.
47. Blass EM, Fitzgerald E, Kehoe P: Interactions between sucrose, pain, and isolation distress. Pharmacol Biochem Behav. 1987; 26: 483-489.
48. Mitchell A, Waltman PA: Oral sucrose and pain relief for preterm infants. Pain Manag Nurs. 2003; 4(2): 62-69.
49. Ramenghi LA, Wood CM, Griffith GC, et al.: Reduction of pain response in premature infants using intraoral sucrose. Arch Dis Child. 1996; 74: F126-F128.
50. Ramenghi LA, Griffith GC, Wood LA, et al.: Effects of nonsucrose sweet tasting solution on neonatal heel prick responses. Arch Dis Child. 1996; 74(2): F129-F131.
51. Ramenghi LA, Evans DJ, Levene ME: Sucrose analgesia: Absorptive mechanism or taste perception? Arch Dis Child Fetal Neonatal Ed. 1999; 80:146-147.
52. Barr RG, Pantel MS, Young SN, et al.: The response of crying newborns to sucrose: Is it a "sweetness" effect? Physiol Behav. 1999; 66(3): 409-417.
53. Blass EM, Ciaramitaro V: Oral determinants of state, affect, and action in newborn humans. Monogr Soc Res Child Dev. 1994; 59: 1-96.
54. Taddio A, Shah V, Shah P, et al.: B-Endorphin concentration after administration of sucrose in preterm infants. Arch Pediatr Adolesc Med. 2003; 157:1071-1074.
55. Miller A, Barr RG, Young SN: The cold pressor test in children: Methodological aspects and the analgesic effect of intraoral sucrose. Pain. 1994; 56: 175-183.
56. Mercer ME, Holder MD: Antinociceptive effects of palatable sweet ingesta on human responsivity to pressure pain. Physiol Behav. 1997; 61(2): 311-318.
57. Anseloni VCZ, Weng HR, Terayama R, et al.: Age-dependency of analgesia elicited by intraoral sucrose in acute and persistent pain models. Pain. 2002; 97(1-2): 93-103.
58. Lewkowski MD, Barr RG, Sherrard A, et al.: Effects of chewing gum on responses to routine painful procedures in children. Physiol Behav. 2003; 79(2): 257-265.
59. Lewkowski MD, Young SN, Ghosh S, et al.: Effects of opioid blockade on the modulation of pain and mood by sweet taste and blood pressure in young adults. Pain. 2008; 135: 75-81.
60. Fontella FU, Nunes ML, Crema LM, et al.: Taste modulation of nociception differently affects chronically stressed rats. Physiol Behav. 2004; 80: 557-561.
61. Kanarek RB, Homoleski B: Modulation of morphine-induced antinociception by palatable solutions in male and female rats. Pharmacol Biochem Behav. 2000; 66(3): 653-659.
62. Klein SP, Green KF: Tolerance to morphine analgesia from brief exposure to a palatable solution. Brain Res Bull. 1988; 21: 963-965.
63. Reece AS: Dentition of addiction in Queensland: Poor dental status and major contributing drugs. Aust Dent J. 2007; 52(2): 144-149.
64. Titsas A, Ferguson MM: Impact of opioid use on dentistry. Aust Dent J. 2002; 47(2): 94-98.
65. Reece AS: An intriguing association between dental and mental pathology in addicted and control subjects: A cross-sectional survey. Br Dent J. 2008; 205(E22): 1-8.
66. Nathwani NS, Gallagher JE: Methadone: Dental risks and preventive action. Dent Update. 2008; 35(8): 542-544, 547-548.
67. Federman AD, Arnsten JH: Primary care affiliations of adults in a methadone program with onsite care. J Addict Dis. 2007; 26(1): 27-34.
68. Spiegel TA, Stunkard AJ, Shrager EE, et al.: Effect of naltrex-one on food intake, hunger, and satiety in obese men. Physiol Behav. 1987; 40(2): 135-141.
69. Atkinson RL, Berle LK, Drake CR, et al.: Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther. 1985; 38(4): 419-422.
70. Maggio CA, Presta E, Bracco EF, et al.: Naltrexone and human eating behavior: A dose-ranging inpatient trial in moderately obese men. Brain Res Bull. 1985; 14(6): 657-661.
71. Mitchell JE, Morley JE, Levine AS, et al.: High-dose naltrex-one therapy and dietary counseling for obesity. Biol Psychiatry. 1987; 221(1): 35-42.
72. Malcolm R, O'Neil PM, Sexauer JD, et al.: A controlled trial of naltrexone in obese humans. IntJ Obes. 1985; 9(5): 347-353.
73. Pfohl DN, Allen JI, Atkinson RL, et al.: Naltrexone hydrochloride (Trexan): A review of serum transaminase elevations at high dosage. NIDA Res Monogr. 1986; 67: 66-72.
74. Orexigen Press Release: Contrave® obesity research phase 3 program meets co-primary and key secondary endpoints; Exceeds FDA efficacy benchmark for obesity treatments, San Diego. Available at www.Orexigen.com. Accessed July 20, 2009.
75. Greenway FL, Whitehouse MJ, Guttadauria M, et al.: Rational design of a combination medication for the treatment of obesity. Obesity. 2009; 17(1): 30-39.
76. Greenway FL, Dunayevich E, Tollefson G, et al.: Comparison of combined buproprion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009; 94(12): 4898-4906.
77. Recant L, Voyles NR, Luciano M, et al.: Naltrexone reduces weight gain, alters "beta-endorphin", and reduces insulin output from pancreatic islets of genetically obese mice. Peptides. 1908; 1(4): 309-313.
78. De Marinis L, Mancini A, Valle D, et al.: Influence of chronic naltrexone treatment on growth hormone and insulin secretion in obese subjects. Int J Obes Relat Metab Disord. 1997; 21(11): 1076-1081. (Pubitemid 27462415)
79. Dey PK, Feldberg W: Hyperglycemia produced by drugs with analgesic properties introduced into cerebral ventricles of cats. Br J Pharmacol. 1975; 54: 163-170.